T-DM1 and the Dawn of Precision MedicineT-DM1 and the Dawn of Precision Medicine

Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Publication date: 16 July 2019Source: Cell Reports, Volume 28, Issue 3Author(s): Pavel Bouchal, Olga T. Schubert, Jakub Faktor, Lenka Capkova, Hana Imrichova, Karolina Zoufalova, Vendula Paralova, Roman Hrstka, Yansheng Liu, Holger Alexander Ebhardt, Eva Budinska, Rudolf Nenutil, Ruedi AebersoldSummaryAccurate classification of breast tumors is vital for patient management decisions and enables more precise cancer treatment. Here, we present a quantitative proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry and establish key proteins for breast tu...
Source: Cell Reports - Category: Cytology Source Type: research
HER2 (human epidermal growth factor receptor 2) is a protein that is associated with some particularly aggressive forms of breast cancer. The presence of high concentrations of this protein seems to lead to the growth of tumors, so inactivating HER2 ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Ob/Gyn Oncology Source Type: blogs
CONCLUSIONS: Adjuvant trastuzumab has substantially improved the survival of patients with HER2+ eBC, contributing over 41,000 LYG to Spanish society (over 36,000 DFLYG) in a cost-effective manner. However, the sum of LYG with trastuzumab is still far from the LY estimated for the general population, supporting the need of further advances in HER2+ eBC. PMID: 31303965 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion.The HER2‐enriched subtype was identified in a substantial proportion of advanced HR+/HER2‐negative breast tumors, and was a consistent biomarker of poor prognosis. Tailored therapies are therefore needed for HER2‐enriched tumors in the advanced HR+/HER2‐negative breast cancer setting.Implications for Practice.Using 261 tumor samples from the BOLERO‐2 phase III clinical trial, this study shows that a substantial proportion (20%–30%) of hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2 (HER2)‐negative advanced breast cancers do not have a luminal A or B gene expression pr...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeLimited evidence exists on the impact of hormone receptor (HR) status to counsel HER2-positive early breast cancer patients receiving adjuvant anti-HER2 therapy.MethodsALTTO (BIG 2-06) was an international, intergroup, open-label, randomized phase III trial in HER2-positive early breast cancer patients randomized to receive 1  year of trastuzumab and/or lapatinib. HER2, estrogen and progesterone receptors were centrally tested for all patients. We investigated the impact of HR status on prognosis, risk of disease-free survival (DFS) events over time, patterns of first DFS events, and factors associated ...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Triple negative breast cancer (TNBC) is a breast cancer subgroup characterized by a lack of hormone receptors ’ expression and no HER2 overexpression. These molecular features both drastically reduce treatment ...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
ConclusionWe demonstrated a new approach of NIR-PIT utilizing a target on vascular endothelium, such as VEGFR-2, and this treatment might lead to the development of a new therapeutic strategy for human gastric cancer.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
AbstractPurposeCurrently, the most commonly used chelator for labelling antibodies with89Zr for immunoPET is desferrioxamine B (DFO). However, preclinical studies have shown that the limited in vivo stability of the89Zr-DFO complex results in release of89Zr, which accumulates in mineral bone. Here we report a novel chelator DFOcyclo*, a preorganized extended DFO derivative that enables octacoordination of the89Zr radiometal. The aim was to compare the in vitro and in vivo stability of [89Zr]Zr-DFOcyclo*, [89Zr]Zr-DFO* and [89Zr]Zr-DFO.MethodsThe stability of89Zr-labelled chelators alone and after conjugation to trastuzumab...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer & Oncology | Health | Hematology | HER2 | Herceptin